| abstract |
The present invention relates to i) HCMV antigen polypeptide gH, gL, UL128, UL130, and / or UL131A, ii) HCMV antigen polypeptide gB, iii) HCMV antigen polypeptide pp65, and iv) a pharmaceutically acceptable carrier or HCMV ribonucleic acid (RNA) vaccine encoding excipients. It also relates to an HCMV polypeptide vaccine comprising (i) to (iv), an HCMV mRNA vaccine comprising an HCMV antigen, and methods for using the vaccine and compositions thereof. |